Bringing Safe and Standardized Cell Therapies to Industrialized Processing for Burns and Wounds
Alexis Laurent, Poyin Lin, Corinne Scaletta, Nathalie Hirt-Burri, Murielle Michetti, Anthony S de Buys Roessingh, Wassim Raffoul, Bin-Ru She, Lee Ann Applegate, Alexis Laurent, Poyin Lin, Corinne Scaletta, Nathalie Hirt-Burri, Murielle Michetti, Anthony S de Buys Roessingh, Wassim Raffoul, Bin-Ru She, Lee Ann Applegate
Abstract
Cultured primary progenitor cell types are worthy therapeutic candidates for regenerative medicine. Clinical translation, industrial transposition, and commercial implementation of products based on such cell sources are mainly hindered by economic or technical barriers and stringent regulatory requirements. Applied research in allogenic cellular therapies in the Lausanne University Hospital focuses on cell source selection technique optimization. Use of fetal progenitor cell sources in Switzerland is regulated through Federal Transplantation Programs and associated Fetal Biobanks. Clinical applications of cultured primary progenitor dermal fibroblasts have been optimized since the 1990s as "Progenitor Biological Bandages" for pediatric burn patients and adults presenting chronic wounds. A single organ donation procured in 2009 enabled the establishment of a standardized cell source for clinical and industrial developments to date. Non-enzymatically isolated primary dermal progenitor fibroblasts (FE002-SK2 cell type) served for the establishment of a clinical-grade Parental Cell Bank, based on a patented method. Optimized bioprocessing methodology for the FE002-SK2 cell type has demonstrated that extensive and consistent progenitor cell banks can be established. In vitro mechanistic characterization and in vivo preclinical studies have confirmed potency, preliminary safety and efficacy of therapeutic progenitor cells. Most importantly, highly successful industrial transposition and up-scaling of biobanking enabled the establishment of tiered Master and Working Cell Banks using Good Manufacturing Practices. Successive and successful transfers of technology, know-how and materials to different countries around the world have been performed. Extensive developments based on the FE002-SK2 cell source have led to clinical trials for burns and wound dressing. Said trials were approved in Japan, Taiwan, USA and are continuing in Switzerland. The Swiss Fetal Transplantation Program and pioneer clinical experience in the Lausanne Burn Center over three decades constitute concrete indicators that primary progenitor dermal fibroblasts should be considered as therapeutic flagships in the domain of wound healing and for regenerative medicine in general. Indeed, one single organ donation potentially enables millions of patients to benefit from high-quality, safe and effective regenerative therapies. This work presents a technical and translational overview of the described progenitor cell technology harnessed in Switzerland as cellular therapies for treatment of burns and wounds around the globe.
Keywords: GMP manufacturing; burns; cell therapy; chronic wounds; clinical cell banking; fibroblasts; progenitor cells.
Copyright © 2020 Laurent, Lin, Scaletta, Hirt-Burri, Michetti, de Buys Roessingh, Raffoul, She and Applegate.
Figures
References
- Abbasalizadeh S., Baharvand H. (2013). Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol. Adv. 31, 1600–1623. 10.1016/j.biotechadv.2013.08.009
- Abbasalizadeh S., Pakzad M., Cabral J. M. S., Baharvand H. (2017). Allogeneic cell therapy manufacturing: process development technologies and facility design options. Expert Opin. Biol. Ther. 17, 1201–1219. 10.1080/14712598.2017.1354982
- Abdel-Sayed P., Hirt-Burri N., de Buys Roessingh A. S., Raffoul W., Applegate L. A. (2019). Evolution of biological bandages as first cover for burn patients. Adv. Wound Care 8, 555–564. 10.1089/wound.2019.1037
- Abdel-Sayed P., Kaeppeli A., Siriwardena T., Darbre T., Perron K., Jafari P., et al. (2016). Anti-microbial dendrimers against multidrug-resistant P. aeruginosa enhance the angiogenic effect of biological burn-wound bandages. Sci. Rep. 6:22020 10.1038/srep23872
- Akita S., Akino K., Imaizumi T., Hirano A. (2008). Basic fibroblast growth factor accelerates and improves second-degree burn wound healing. Wound Repair Regen. 16, 635–641. 10.1111/j.1524-475X.2008.00414.x
- Antsiferova M., Klatte J. E., Bodó E., Paus R., Jorcano J. L., Matzuk M. M., et al. . (2009). Keratinocyte-derived follistatin regulates epidermal homeostasis and wound repair. Lab. Invest. 89, 131–141. 10.1038/labinvest.2008.120
- Applegate L. A., Scaletta C., Hirt-Burri N., Raffoul W., Pioletti D. (2009). Whole-cell bioprocessing of human fetal cells for tissue engineering of skin. Skin Pharmacol. Physiol. 22, 63–73. 10.1159/000178865
- Applegate L. A., Weber D., Simon J. P., Scaletta C., Hirt-Burri N., de Buys Roessingh A. S., et al. . (2013). Organ donation and whole-cell bioprocessing in the Swiss fetal progenitor cell transplantation platform, in Organ Donation and Organ Donors. ed Saidi R. F. (Nova Science Publishers; ), 125–147.
- Bach A. D., Arkudas A., Tjiawi J., Polykandriotis E., Kneser U., Horch R. E., et al. . (2006). A new approach to tissue engineering of vascularized skeletal muscle. J. Cell. Mol. Med. 10, 716–726. 10.1111/j.1582-4934.2006.tb00431.x
- Barrientos S., Stojadinovic O., Golinko M. S., Brem H., Tomic-Canic M. (2008). Growth factors and cytokines in wound healing. Wound Repair Regen. 16, 585–601. 10.1111/j.1524-475X.2008.00410.x
- Borda L. J., Macquhae F. E., Kirsner R. S. (2016). Wound dressings: a comprehensive review. Curr. Derm. Rep. 5, 287–297. 10.1007/s13671-016-0162-5
- Cass D. L., Meuli M., Adzick N. S. (1997). Scar wars: implications of fetal wound healing for the pediatric burn patient. Pediatr. Surg. Int. 12, 484–489. 10.1007/BF01258707
- Chen H. L., Chiang P. C., Lo C. H., Lo Y. H., Hsu D. K., Chen H. Y., et al. . (2016). Galectin-7 regulates keratinocyte proliferation and differentiation through JNK-miR-203-p63 signaling. J. Invest. Dermatol. 136, 182–191. 10.1038/JID.2015.366
- Costa-Almeida R., Calejo I., Gomes M. E. (2019). Mesenchymal stem cells empowering tendon regenerative therapies. Int. J. Mol. Sci. 20:3002. 10.3390/ijms20123002
- De Buys Roessingh A. S., Hirt-Burri N., Raffoul W., Scaletta C., Applegate L. A. (2015). A decade after foetal skin progenitor cell therapy in pediatric burn treatment. J. Regen. Med. 4:1 10.4172/2325-9620.1000122
- De Buys Roessingh A. S., Hohlfeld J., Scaletta C., Hirt-Burri N., Gerber S., Hohlfeld P., et al. . (2006). Development, characterization, and use of a fetal skin cell bank for tissue engineering in wound healing. Cell Transplant. 15, 823–834. 10.3727/000000006783981459
- Dhivya S., Padma V. V., Santhini E. (2015). Wound dressings - a review. Biomedicine 5:22. 10.7603/s40681-015-0022-9
- Doyle A., Griffiths J. B. (1998). Cell and Tissue Culture: Laboratory Procedures in Biotechnology. New York, NY: Wiley & Sons.
- Gallucci R. M., Simeonova P. P., Matheson J. M., Kommineni C., Guriel J. L., Sugawara T., et al. . (2000). Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 14, 2525–2531. 10.1096/fj.00-0073com
- Grognuz A., Scaletta C., Farron A., Raffoul W., Applegate L. A. (2016). Human fetal progenitor tenocytes for regenerative medicine. Cell Transplant. 25, 463–479. 10.3727/096368915X688515
- Haack-Sørensen M., Kastrup J. (2011). Cryopreservation and revival of mesenchymal stromal cells. Methods Mol. Biol. 698, 161–174. 10.1007/978-1-60761-999-4_13
- Hayflick L., Plotkin S. A., Norton T. W., Koprowski H. (1962). Preparation of poliovirus vaccines in a human fetal diploid cell strain. Am. J. Hyg. 75, 240–258. 10.1093/oxfordjournals.aje.a120247
- Heathman T. R., Nienow A. W., McCall M. J., Coopman K., Kara B., Hewitt C. J. (2015). The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen. Med. 10, 49–64. 10.2217/rme.14.73
- Hebda P. A., Dohar J. E. (1999). Transplanted fetal fibroblasts: Survival and distribution over time in normal adult dermis compared with autogenic, allogenic, and xenogenic adult fibroblasts. Otolaryngol. Head Neck Surg. 121, 245–251. 10.1016/S0194-5998(99)70179-8
- Hernon C. A., Dawson R. A., Freedlander E., Short R., Haddow D. B., Brotherston, et al. (2006). Clinical experience using cultured epithelial autografts leads to an alternative methodology for transferring skin cells from the laboratory to the patient. Regen. Med. 1, 809–821. 10.2217/17460751.1.6.809
- Hohlfeld J., de Buys Roessingh A. S., Hirt-Burri N., Chaubert P., Gerber S., Scaletta C., et al. . (2005). Tissue engineered fetal skin constructs for paediatric burns. Lancet 366, 840–842. 10.1016/S0140-6736(05)67107-3
- Hunsberger J., Harrysson O., Shirwaiker R., Starly B., Wysk R., Cohen P., et al. . (2015). Manufacturing road map for tissue engineering and regenerative medicine technologies. Stem Cells Transl. Med. 4, 130–135. 10.5966/sctm.2014-0254
- Hunt C. J. (2019). Technical considerations in the freezing, low-temperature storage and thawing of stem cells for cellular therapies. Transfus. Med. Hemother. 46, 134–150. 10.1159/000497289
- Jiang W. G., Sanders A. J., Ruge F., Harding K. G. (2012). Influence of interleukin-8 (IL-8) and IL-8 receptors on the migration of human keratinocytes, the role of PLC-γ and potential clinical implications. Exp. Ther. Med. 3, 231–236. 10.3892/etm.2011.402
- Kim H. R., Kim J., Park S. R., Min B. H., Choi B. H. (2018). Characterization of human fetal cartilage progenitor cells during long-term expansion in a xeno-free medium. Tissue Eng. Regen. Med. 15, 649–659. 10.1007/s13770-018-0132-z
- Krishnaswamy V. R., Mintz D., Sagi I. (2017). Matrix metalloproteinases: The sculptors of chronic cutaneous wounds. Biochim. Biophys. Acta Mol. Cell Res. 1864(Pt. B), 2220–2227. 10.1016/j.bbamcr.2017.08.003
- Kroeze K. L., Boink M. A., Sampat-Sardjoepersad S. C., Waaijman T., Scheper R. J., Gibbs S. (2012). Autocrine regulation of re-epithelialization after wounding by chemokine receptors CCR1, CCR10, CXCR1, CXCR2, and CXCR3. J. Invest. Dermatol. 132, 216–225. 10.1038/jid.2011.245
- Larijani B., Ghahari A., Warnock G. L., Aghayan H. R., Goodarzi P., Falahzadeh K., et al. . (2015). Human fetal skin fibroblasts: extremely potent and allogenic candidates for treatment of diabetic wounds. Med. Hypotheses 84, 577–579. 10.1016/j.mehy.2015.03.004
- Laurent-Applegate L. A. (2012). Preparation of Parental Cell Bank from Foetal Tissue. European Patent No 2,732,030,B1. Munich: European Patent Office.
- Li Z., Maitz P. (2018). Cell therapy for severe burn wound healing. Burns Trauma 6:13. 10.1186/s41038-018-0117-0
- Loebel C., Burdick J. A. (2018). Engineering stem and stromal cell therapies for musculoskeletal tissue repair. Cell Stem Cell. 22, 325–339. 10.1016/j.stem.2018.01.014
- Marks P., Gottlieb S. (2018). Balancing safety and innovation for cell-based regenerative medicine. N. Engl. J. Med. 378, 954–959. 10.1056/NEJMsr1715626
- Metcalfe A. D., Ferguson M. W. (2008). Skin stem and progenitor cells: using regeneration as a tissue-engineering strategy. Cell. Mol. Life Sci. 65, 24–32. 10.1007/s00018-007-7427-x
- Mirmalek-Sani S. H., Tare R. S., Morgan S. M., Roach H. I., Wilson D. I., Hanley N. A., et al. . (2006). Characterization and multipotentiality of human fetal femur-derived cells: implications for skeletal tissue regeneration. Stem Cells 24, 1042–1053. 10.1634/stemcells.2005-0368
- Monti M., Perotti C., Del Fante C., Cervio M., Redi C. A. (2012). Stem cells: sources and therapies. Biol. Res. 45, 207–214. 10.4067/S0716-97602012000300002
- Montjovent M. O., Burri N., Mark S., Federici E., Scaletta C., Zambelli P. Y., et al. . (2004). Fetal bone cells for tissue engineering. Bone 35, 1323–1333. 10.1016/j.bone.2004.07.001
- Mount N. M., Ward S. J., Kefalas P., Hyllner J. (2015). Cell-based therapy technology classifications and translational challenges. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370:20150017. 10.1098/rstb.2015.0017
- Olshansky S. J., Hayflick L. (2017). The role of the WI-38 cell strain in saving lives and reducing morbidity. AIMS Public Health 4, 127–138. 10.3934/publichealth.2017.2.127
- Pastar I., Stojadinovic O., Yin N. C., Ramirez H., Nusbaum A. G., Sawaya A., et al. . (2014). Epithelialization in wound healing: a comprehensive review. Adv. Wound Care 3, 445–464. 10.1089/wound.2013.0473
- Pigeau G. M., Csaszar E., Dulgar-Tulloch A. (2018). Commercial scale manufacturing of allogeneic cell therapy. Front. Med. 5:233. 10.3389/fmed.2018.00233
- Providence K. M., Higgins S. P., Mullen A., Battista A., Samarakoon R., Higgins C. E., et al. . (2008). SERPINE1 (PAI-1) is deposited into keratinocyte migration “trails” and required for optimal monolayer wound repair. Arch. Dermatol. Res. 300, 303–310. 10.1007/s00403-008-0845-2
- Quintin A., Hirt-Burri N., Scaletta C., Schizas C., Pioletti D. P., Applegate L. A. (2007). Consistency and safety of cell banks for research and clinical use: preliminary analysis of fetal skin banks. Cell Transplant. 16, 675–684. 10.3727/000000007783465127
- Ramelet A. A., Hirt-Burri N., Raffoul W., Scaletta C., Pioletti D. P., Offord E., et al. . (2009). Chronic wound healing by fetal cell therapy may be explained by differential gene profiling observed in fetal versus old skin cells. Exp. Gerontol. 44, 208–218. 10.1016/j.exger.2008.11.004
- Ratcliffe E., Thomas R. J., Williams D. J. (2011). Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine. Br. Med. Bull. 100, 137–155. 10.1093/bmb/ldr037
- Rayment E. A., Williams D. J. (2010). Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 28, 996–1004. 10.1002/stem.416
- Rheinwald J. G., Green H. (1975). Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6, 331–343. 10.1016/S0092-8674(75)80001-8
- Scholz F., Schulte A., Adamski F., Hundhausen C., Mittag J., Schwarz A., et al. . (2007). Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. J. Invest. Dermatol. 127, 1444–1455. 10.1038/sj.jid.5700751
- Shah M., Foreman D. M., Ferguson M. W. J. (1992). Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet 339, 213–214. 10.1016/0140-6736(92)90009-R
- Simman R., Phavixay L. (2011). Split-thickness skin grafts remain the gold standard for the closure of large acute and chronic wounds. J. Am. Col. Certif. Wound Spec. 3, 55–59. 10.1016/j.jcws.2012.03.001
- Sobel K., Tham M., Stark H. J., Stammer H., Prätzel-Wunder S., Bickenbach J. R., et al. . (2015). Wnt-3a-activated human fibroblasts promote human keratinocyte proliferation and matrix destruction. Int. J. Cancer 136, 2786–2798. 10.1002/ijc.29336
- Spiekstra S. W., Breetveld M., Rustemeyer T., Scheper R., Gibbs S. (2007). Wound-healing factors secreted by epidermal keratinocytes and dermal fibroblasts in skin substitutes. Wound Repair Regen. 15, 708–717. 10.1111/j.1524-475X.2007.00280.x
- Tan K. K. B., Salgado G., Connolly J. E., Chan J. K. Y., Lane E. B. (2014). Characterization of fetal keratinocytes, showing enhanced stem cell-like properties: a potential source of cells for skin reconstruction. Stem Cell Rep. 3, 324–338. 10.1016/j.stemcr.2014.06.005
- Usui M. L., Mansbridge J. N., Carter W. G., Fujita M., Olerud J. E. (2008). Keratinocyte migration, proliferation, and differentiation in chronic ulcers from patients with diabetes and normal wounds. J. Histochem. Cytochem. 56, 687–696. 10.1369/jhc.2008.951194
- Vacanti J. P., Langer R. (1999). Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet 354(Suppl. 1), SI32–S134. 10.1016/S0140-6736(99)90247-7
- Varkey M., Ding J., Tredget E. E. (2015). Advances in skin substitutes-potential of tissue engineered skin for facilitating anti-fibrotic healing. J. Funct. Biomater. 6, 547–563. 10.3390/jfb6030547
- Werner S., Krieg T., Smola H. (2007). Keratinocyte-fibroblast interactions in wound healing. J. Invest. Dermatol. 127, 998–1008. 10.1038/sj.jid.5700786
- Wojtowicz A. M., Oliveira S., Carlson M. W., Zawadzka A., Rousseau C. F., Baksh D. (2014). The importance of both fibroblasts and keratinocytes in a bilayered living cellular construct used in wound healing. Wound Repair Regen. 22, 246–255. 10.1111/wrr.12154
- Zaja-Milatovic S., Richmond A. (2008). CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol. Histopathol. 23, 1399–1407. 10.14670/HH-23.1399
- Zuliani T., Saiagh S., Knol A. C., Esbelin J., Dréno B. (2013). Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy. PLoS ONE 8:e70408. 10.1371/journal.pone.0070408
Source: PubMed